A Novel Approach of Targeted Immunotherapy against Adenocarcinoma Cells with Nanoparticles Modified by CD16 and MUC1 Aptamers

Figure 5

Evaluation of the binding of aptamer-modified NP to target cells by competition study. Cells were incubated with FAM-labeled aptamer. Free aptamer, aptamer-modified NP, or blank NP was added to compete for the binding sites on these cells, which were analyzed by flow cytometry. (a) A549 cells incubated with FAM-labeled MUC1 aptamer (blue line) and competed with MUC1-NP (red line), MUC1 aptamer (green line), or blank NP (purple line). (b) PBMC incubated with FAM-labeled CD16 aptamer (blue line) and competed with CD16-NP (red line), CD16 aptamer (green line), and blank NP (purple line). (c) A549 cells incubated with FAM-labeled MUC1 aptamer (blue line) and competed with HER2-NP (red line) and MUC1 aptamer (green line).

(a)

(b)

(c)